Latest Breaking News On - Scopus biopharma - Page 1 : comparemela.com

7+ Companies That Had Their IPO in 2020: Best and Worst Performers

2020 will forever be remembered as the year the coronavirus pandemic broke out. But in the year of the lockdowns, there were also 480 initial public offerings on the U.S. stock market — a record high at the time, according to Stock Analysis. Only 2021 had more IPOs. With nearly 500 IPOs, naturally many of […]

Scopus BioPharma's Subsidiary — Duet BioTherapeutics —

DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of.

Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presentin

Scopus BioPharma's Subsidiary - Duet BioTherapeutics - to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer